Bempedoic acid update: efficacy not clinically relevant – medicine.nl

Research from 2023 on the effectiveness of bempedoic acid on cardiovascular outcomes shows limited effectiveness, but possible adverse effects.

Two network meta-analyses from 2022 show that bempedoic acid is the most effective cholesterol-lowering drug that can be used as an alternative to statins, even more effective than the moderately effective cholesterol-lowering ezetimibe.

So bempedoic acid is not the first choice in the treatment of hypercholesterolemia.

Determination of Ge-Bu position

What is the position of the Ge-Bu?

• Bempedoic acid is only suitable in exceptional cases as a new treatment for people with total statin intolerance or as an addition to statin treatment that is not effective enough, even after adding ezetimibe.

• Compared to placebo, bempedoic acid has low to moderate efficacy on cardiovascular outcomes in patients at high cardiovascular risk. More than 60 patients must be treated for about 3.5 years to prevent one cardiovascular event.

• Bempedoic acid has fewer muscle-related side effects than statins, but the severity and potential side effects such as kidney dysfunction and increases in blood pressure are still unclear. liver enzymes

• A network meta-analysis shows that bempedoic acid may be the most effective alternative to statins in lowering LDL cholesterol.

Read the full article